Kiniksa Pharmaceuticals, Ltd. (KNSA)
KNSA Stock Price Chart
Explore Kiniksa Pharmaceuticals, Ltd. interactive price chart. Choose custom timeframes to analyze KNSA price movements and trends.
KNSA Company Profile
Discover essential business fundamentals and corporate details for Kiniksa Pharmaceuticals, Ltd. (KNSA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 May 2018
Employees
315.00
Website
https://www.kiniksa.comCEO
Sanj K. Patel
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
KNSA Financial Timeline
Browse a chronological timeline of Kiniksa Pharmaceuticals, Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Nov 2025
EPS estimate is $0.31.
Earnings released on 29 Jul 2025
EPS came in at $0.23 surpassing the estimated $0.18 by +27.78%, while revenue for the quarter reached $156.80M , missing expectations by -5.96%.
Earnings released on 29 Apr 2025
EPS came in at $0.11 surpassing the estimated $0.02 by +450.00%, while revenue for the quarter reached $137.79M , beating expectations by +4.48%.
Earnings released on 25 Feb 2025
EPS came in at -$0.12 falling short of the estimated -$0.06 by -100.00%, while revenue for the quarter reached $122.54M , missing expectations by -0.71%.
Earnings released on 29 Oct 2024
EPS came in at -$0.18 falling short of the estimated -$0.02 by -662.39%, while revenue for the quarter reached $112.21M , missing expectations by -9.05%.
Earnings released on 23 Jul 2024
EPS came in at -$0.06 surpassing the estimated -$0.09 by +33.33%, while revenue for the quarter reached $108.63M , missing expectations by -1.51%.
Earnings released on 23 Apr 2024
EPS came in at -$0.25 falling short of the estimated -$0.14 by -78.57%, while revenue for the quarter reached $79.86M , beating expectations by +1.78%.
Earnings released on 28 Feb 2024
EPS came in at $0.04 surpassing the estimated -$0.11 by +136.36%, while revenue for the quarter reached $83.40M , beating expectations by +15.79%.
Earnings released on 31 Oct 2023
EPS came in at -$0.20 falling short of the estimated -$0.18 by -11.11%, while revenue for the quarter reached $67.05M , beating expectations by +4.03%.
Earnings released on 25 Jul 2023
EPS came in at -$0.02 surpassing the estimated -$0.16 by +87.50%, while revenue for the quarter reached $71.47M , beating expectations by +14.91%.
Earnings released on 2 May 2023
EPS came in at -$0.18 matching the estimated -$0.18, while revenue for the quarter reached $48.35M , beating expectations by +3.79%.
Earnings released on 28 Feb 2023
EPS came in at $0.06 surpassing the estimated -$0.23 by +126.09%, while revenue for the quarter reached $61.88M , beating expectations by +37.17%.
Earnings released on 1 Nov 2022
EPS came in at $0.67 surpassing the estimated $0.38 by +76.32%, while revenue for the quarter reached $99.14M , beating expectations by +5.94%.
Earnings released on 3 Aug 2022
EPS came in at -$0.29 surpassing the estimated -$0.43 by +32.56%, while revenue for the quarter reached $26.97M , missing expectations by -5.10%.
Earnings released on 3 May 2022
EPS came in at -$0.36 surpassing the estimated -$0.52 by +30.77%, while revenue for the quarter reached $32.19M , beating expectations by +6.93%.
Earnings released on 22 Feb 2022
EPS came in at -$0.53 falling short of the estimated -$0.44 by -20.45%, while revenue for the quarter reached $18.75M , beating expectations by +6.51%.
Earnings released on 1 Nov 2021
EPS came in at -$0.44 surpassing the estimated -$0.63 by +30.16%, while revenue for the quarter reached $12.10M , beating expectations by +37.76%.
Earnings released on 3 Aug 2021
EPS came in at -$0.61 surpassing the estimated -$0.69 by +11.59%, while revenue for the quarter reached $7.70M , meeting expectations.
Earnings released on 4 May 2021
EPS came in at -$0.72 surpassing the estimated -$0.73 by +1.37%.
Earnings released on 23 Feb 2021
EPS came in at -$0.79 falling short of the estimated -$0.61 by -29.51%.
Earnings released on 5 Nov 2020
EPS came in at -$0.66 falling short of the estimated -$0.59 by -11.86%.
KNSA Stock Performance
Access detailed KNSA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.